
Juul can continue selling its tobacco and menthol e-cigarettes, FDA says
'This is an important milestone for the company and I think we made a scientifically sound case for the role that menthol can play in e-vapor,' Juul CEO K.C. Crosthwaite told The Associated Press.
Parents, politicians and antitobacco groups are certain to oppose FDA's decision. They have argued for years that Juul should be permanently banned from selling its products due to its role in triggering a yearslong spike in underage vaping
Advertisement
Juul was once valued at over $13 billion and its small, sleek e-cigarettes revolutionized the image and technology of the vaping industry. But the company has since been forced to slash hundreds of jobs and pay billions to settle lawsuits over its role in the rise of youth vaping.
The FDA had ordered the company to remove its products from the market in June 2022. But then the agency abruptly reversed course days later and agreed to reopen its scientific review of Juul's application after the company pushed back in court.
Advertisement
Juul said that regulators had overlooked thousands of pages of scientific data critical to its submission.
Thursday's announcement is not an approval or endorsement, and the FDA reiterated that people who do not smoke should not use Juul or any other e-cigarettes. The FDA determination indicates that smokers who switch completely to Juul can reduce their exposure to deadly carcinogens and other chemicals found in traditional cigarettes.
The FDA decision applies to Juul's original product, which is now roughly a decade old. Crosthwaite said the company hopes to win authorization for its next-generation device and is also considering applying to FDA for more flavors.
In recent years, the FDA has authorized a handful of e-cigarettes to help adult smokers cut back on traditional cigarettes, while rejecting more than a million other vaping products that failed to meet agency standards. Juul's main competitors, Vuse and Njoy, each previously received FDA permission to remain on the market.
To meet FDA requirements, companies must show that their e-cigarettes benefit public health. In practice, that means proving that adult smokers who use them are likely to quit or reduce their smoking, while teens are unlikely to get hooked on them.
The brainchild of two Stanford University students, Juul launched in 2015 and within two years rocketed to the top of the vaping market.
Juul quickly outpaced earlier brands with its high-nicotine, fruity-flavored cartridges, sold in mango, mint and creme brulé. The company's small, discrete devices provided a more potent, user-friendly alternative to older, bulkier devices.
Advertisement
But the company's rise was fueled by underage use, and e-cigarettes quickly became ubiquitous in U.S. schools. In 2019, the company was pressured into halting all advertising and eliminating most of its flavors, leaving only tobacco and menthol-flavored options.
By then the company was already the target of multiple investigations and lawsuits by federal, state and local officials as well as class action attorneys.
In 2022, the company paid $1.7 billion to settle thousands of lawsuits brought by families of Juul users, school districts, city governments and Native American tribes. The company separately agreed to pay $1.1 billion to settle lawsuits or investigations from most US states.
Juul is no longer the top-selling e-cigarette brand and now trails Vuse, which is sold by Reynolds American.
Teens have also shifted away from the brand amid a wider drop in vaping, according to the latest federal survey. The FDA reported last year that teen vaping dropped to a 10-year low, after stepped up enforcement against unauthorized brands imported from China, such as Elf Bar.
Unlike Juul, disposable e-cigarettes like Elf Bar still come in fruit and candy flavors, despite efforts by regulators to block their use.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected
InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its Phase 3 trial for vilobelimab in pyoderma gangrenosum/PG would be discontinued due to futility. The recommendation came from the Independent Data Monitoring Committee/IDMC after an unblinded interim analysis of data from the first 30 enrolled patients. The IDMC noted no unexpected adverse events. Following the recommendation, InflaRx intends to halt further development of vilobelimab for the PG indication. The company will now re-prioritize its resources on INF904, which is an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. Topline Phase 2a data readouts for INF904 in chronic spontaneous urticaria/CSU and hidradenitis suppurativa/HS are anticipated in the summer of 2025. A technician carefully measuring the quality of a nutritional supplement. GOHIBIC (vilobelimab) remains available in the US under an Emergency Use Authorization/EUA granted by the FDA. The authorization is for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation/IMV or extracorporeal membrane oxygenation/ECMO. Vilobelimab is a first-in-class, intravenously delivered, anti-C5a monoclonal antibody that selectively blocks free C5a, which is a potent inflammatory mediator. InflaRx (NASDAQ:IFRX) is a clinical-stage biopharmaceutical company that discovers and develops inhibitors using C5a technology in Germany and the US. While we acknowledge the potential of IFRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
2 hours ago
- Business Wire
REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of the Company's senior executives for potential violations of the federal securities laws. Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of the Company's senior executives for potential violations of the federal securities laws. Share If you invested in Replimune, you are encouraged to obtain additional information by visiting: Investors have until September 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Replimune securities. The case is pending in the U.S. District Court for the District of Massachusetts and is captioned Jboor v. Replimune Group, Inc., et al., No 1:25-cv-12085. Why Was Replimune Sued for Securities Fraud? Replimune is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies for the treatment of cancer. Replimune's lead product candidate is RP1, a treatment for melanoma. On June 6, 2024, the Company announced positive top line results from its IGNYTE Phase 1/2 clinical trial for RP1 in combination with the immunotherapy drug nivolumab. On November 21, 2024, Replimune announced that it had submitted a biologics license application ('BLA') to the FDA for RP1 on the strength of the results of the IGNYTE Phase 1/2 trial. During the relevant period, the Company repeatedly touted the results of the IGNYTE Phase 1/2 trial. In truth, the IGNYTE Phase 1/2 trial design was not adequate to produce reliable results. The Stock Declines as the Truth Is Revealed On July 22, 2025, Replimune announced that it received a Complete Response Letter from the FDA regarding the BLA for RP1. According to the Company, '[t]he FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.' More specifically, 'the FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.' On this news, the price of Replimune stock fell more than 75% on July 22, 2025. Click here for more information: What Can You Do? If you invested in Replimune you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.


Business Wire
2 hours ago
- Business Wire
Theraclion Growth Up in S1 2025
MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, reviews its business for S1 2025. Sales of consumables (recurring revenue) up 30% compared to 2024 New treatment centers opened in Bulgaria and Spain Appointment of a new business manager and acceleration of commercial activities On-schedule completion of the follow-up period for the pivotal FDA clinical trial Martin Deterre, CEO of Theraclion, states: "In early 2025, Theraclion stepped up Sonovein's activity. In June, the final 12-month follow-ups for patients in the pivotal FDA-approved clinical trial were completed on-schedule. We are now awaiting the final results, which we expect to publish in September. Theraclion has also entered a business development phase: building a sales and marketing team, opening two new Sonovein treatment centers, and achieving significant growth in recurring revenue — all of which promise the achievement of our ambitious goals." Commercial activity acceleration As part of its business development, Theraclion is actively building its sales and marketing team. In May 2025, Thibault Le Normand joined the company as Chief Business Officer to boost sales in the Middle East and product placements (PPUs) of Sonovein in Europe. With over a decade of experience in international development of medical devices, Thibault Le Normand brings valuable expertise to this strategic growth phase. At the same time, the technological credibility and clinical maturity of Sonovein have been further demonstrated by the publication of new scientific articles as well as by over a dozen presentations at major international congresses by renowned physicians using the device. Sonovein's international profile has also increased through Theraclion's participation in congresses, such as Vein in Venice (April, Venice), Venous Symposium (May, New York), and the European Venous Forum (June, Krakow). This outreach effort was supported by the launch of a new product identity and a new website, giving Sonovein a new brand image that reflects innovation, clinical excellence, and ambition. In addition, two new product placement (PPU) contracts for Sonovein have been signed in Bulgaria and Spain, stepping up Theraclion's presence in Europe and expanding the installed base of the technology. Revenue for S1 2025 Theraclion's revenue for S1 2025 was €835K, up 89% compared to 2024 (€442K) (prior to the non-recurring adjustment of €680K related to the cancellation of Echopulse system sales in 2024). Consumables, which include recurring revenues from PPUs, was up 30% compared to S1 2024. Service revenues were up 232% over the same period. This strong momentum is a key indicator of increasing use of Sonovein by treatment centers and reflects the technology's sustained traction in the field. Combined, consumables and services — representing recurring revenue — was up 57% compared to 2024. Progress of the pivotal FDA clinical trial In the USA, the pivotal FDA-approved study for SONOVEIN® reached a major milestone in June 2025 with the on-schedule completion of the 12-month post-treatment patient follow-ups. Data analysis is currently underway, with results expected in September. Submission of the marketing authorization application to the FDA is planned for Fall 2025, with potential approval estimated for Q2 2026, subject to the FDA's processing time. This progress marks a critical strategic milestone in the work to access the world's largest market for venous disease treatment. Next financial publication: Theraclion will publish its interim financial results on October 29, 2025. About Theraclion Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound. High Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and patients can immediately resume their routines. HIFU treatment concentrates therapeutic ultrasounds on an internal focal point from outside the body. Theraclion is developing SONOVEIN®, a CE-marked, a robotic platform for HIFU varicose vein treatment, which could replace millions of surgical procedures every year. In the USA, SONOVEIN® is an investigational device limited to investigational use; it is not available for sale in the USA. Based in Malakoff (Paris), the Theraclion team comprises some 30 people, most of them involved in technological and clinical development. Theraclion is listed on Euronext Growth Paris Eligible for the PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI: 9695007X7HA7A1GCYD29